Embecta Corp.
Case Overview
48 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/17/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Embecta Corp. |
| Court: | Court: District of New Jersey |
| Case Number: | Case Number: 2:26cv07217 |
| Class Period: | Class Period: 11/25/2025 - 05/04/2026 |
| Ticker: | Ticker: EMBC |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
The lawsuit alleges that the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Embecta's fiscal results; pertinently, Embecta knew or recklessly disregarded that the Company's guidance was misleading and unattainable.
On May 5, 2026, the Company reported second quarter 2026 earnings, which announced results below analyst expectations and included a reduction to full-year 2026 guidance. The Company stated that the two largest contributors to the results were a “loss within our pen needle product category, most of which is concentrated at a single customer” and “overall market volume softness for insulin pens and pen needles in the retail channel.” As a result of this, the Company also announced “a review of our cost structure and organizational footprint.” On this news, the price of Embecta shares declined by $5.35 per share, or approximately 58%, from $9.25 per share on May 4, 2026 to close at $3.90 on May 5, 2026.
The lawsuit alleges that the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Embecta's fiscal results; pertinently, Embecta knew or recklessly disregarded that the Company's guidance was misleading and unattainable.
On May 5, 2026, the Company reported second quarter 2026 earnings, which announced results below analyst expectations and included a reduction to full-year 2026 guidance. The Company stated that the two largest contributors to the results were a “loss within our pen needle product category, most of which is concentrated at a single customer” and “overall market volume softness for insulin pens and pen needles in the retail channel.” As a result of this, the Company also announced “a review of our cost structure and organizational footprint.” On this news, the price of Embecta shares declined by $5.35 per share, or approximately 58%, from $9.25 per share on May 4, 2026 to close at $3.90 on May 5, 2026.